DCPH - Deciphera Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.76
+0.55 (+0.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close58.21
Open58.40
Bid58.73 x 900
Ask58.79 x 900
Day's Range58.40 - 60.13
52 Week Range19.69 - 60.13
Volume523,031
Avg. Volume487,504
Market Cap3B
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-3.99
Earnings DateNov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.08
  • Hedge Funds Have Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH)

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • Business Wire

    Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

    Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ron Squarer to its Board of Directors. Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. (Array) from 2012 until its acquisition by Pfizer Inc. (Pfizer) in August 2019 following the successful commercial launches of both Braftovi® and Mektovi®.

  • TEST Business Wire Releases

    Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman

    Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has elected Frank S. Friedman to its Board of Directors. Mr. Friedman recently served as the global Chief Operating Officer of Deloitte Touche Tohmatsu Limited (Deloitte), a multinational services organization. Deciphera also announced that Michael Ross, Ph.D., will be stepping down from its Board of Directors.

  • Barrons.com

    Callon, Fitbit, Genco Shipping and Other 13D Filings

    Paulson & Co. disclosed on Nov. 18 an interest in the independent oil-and-gas explorer of 10,338,663 shares, less than half of what Paulson reported on Nov. 5 when it revealed a 9.5% stake. Since the prior disclosure, Paulson shed nearly 52% of its position with sales of 11,254,860 shares at prices ranging from $4.29 to $4.57 each on Nov. 14 and 15, leaving it with a 4.5% interest in Callon’s outstanding stock. Paulson previously stated that it would vote its shares against Callon’s proposed $1.2 billion merger with Carrizo Oil & Gas (CRZO) first announced in July.

  • Business Wire

    Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting

    Deciphera Pharmaceuticals, Inc. (DCPH) today announced preliminary data from the ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including initial data in diffuse-type tenosynovial giant cell tumor (TGCT) patients as well as an encore presentation of the INVICTUS pivotal Phase 3 study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Results from these programs will be presented at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting being held November 13-16 in Tokyo, Japan.

  • Business Wire

    Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

    Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.

  • Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates

    Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -7.56% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results

    - Ripretinib Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors (GI

  • 3 ‘Strong Buy’ Stocks Jefferies Thinks Are Set to Rip Higher
    TipRanks

    3 ‘Strong Buy’ Stocks Jefferies Thinks Are Set to Rip Higher

    Given the market’s latest rally, is it smooth sailing from here? Judging by recent trading activity, some investors are optimistic that this is in fact the case.Jefferies analyst Steven DeSanctis told clients that funds containing stocks from the cyclical sector have seen a $1.5 billion influx since October 4. Stocks in this space can include consumer discretionary, energy as well as information technology names, and tend to perform well when the market is prospering. He added that investors have shifted away from bond proxies, which are seen as a go-to when the economy trends downward.“Although fund flows were muted this past week, under the surface we are seeing some significant changes,” DeSanctis stated.We’ve used TipRanks’ Stock Screener tool to further sort Jefferies' list of stocks to watch for the coming year. These names have earned the rest of the Street’s support as each sports a “Strong Buy” consensus rating. This is based on the calls published by all of the other analysts covering the stock over the last three months. Let’s jump right in.Deciphera (DCPH)Deciphera wants to change the way cancer is treated using its proprietary Kinase Switch Control inhibitor platform. Its lead candidate, ripretinib, was designed as a therapy for digestive tract cancer, with DCPH’s pipeline containing two other products in earlier development.Coming on the heels of promising trial data, Jefferies analyst Eun Yang believes this biotech is well positioned for strong long-term growth.Based on the findings from the Phase 3 INVICTUS trial for ripretinib, the drug was able to cut the risk of disease progression or death by 85% compared to the placebo. Not to mention it more than doubled median overall survival. Yang noted that these results substantially reduce the risks of the drug and give ripretinib the potential to “be the best-in-class therapy”.If that isn’t enough, the analyst predicts peak revenue of $830 million given the potential for an even larger ripretinib market opportunity based on the Phase 3 INTRIGUE trial. That being said, data from this trial isn’t expected until the end of 2020.With its additional candidates also standing to drive upside once further proof-of-concept is available, Yang is convinced that now is the time to buy. This conclusion prompted the 5-star analyst to initiate coverage as well as set a $47 price target. (To watch Yang’s track record, click here)Similarly, other Wall Street analysts like what they’re seeing. With 11 Buy ratings vs 1 Hold received in the last three months, the stock earns a ‘Strong Buy’ Street consensus. At a $53.78 average price target, analysts see 20% upside potential in store for DCPH. (See Deciphera stock analysis on TipRanks)LPL Financial (LPLA)LPL Financial offers financial services as well as customer service to independent financial advisors. Despite the fact that interest rates pose a threat to the company, several analysts argue that its business strategy has put it on the path towards future gains.Jefferies’ Gerald O’Hara cites both the fee-based advisory segment and the independent employee channel as representing key points of strength. Cerulli estimates point to the U.S. retail investment market increasing from its current value of $27 trillion to reach or surpass $32 trillion by 2022, with 75% of this being advice driven. This lends itself to O’Hara’s conclusion that “LPLA is positioned to take share within the $5 trillion fee-based segment (~2% market share) and $4 trillion independent employee channel."On top of this, management is looking to further expand its capabilities across the advice driven wealth management spectrum. “The expanded addressable market (Play 1) will enable LPLA to broaden its opportunity set from about 25% of the wealth management market, to over 60% as it looks to increase penetration on the fee-based businesses and enter a portion of the approximately $11 trillion traditional employee segment,” O’Hara commented.With LPLA primed to see additional upside from higher fee portfolio construction and premium services in the next few years, the five-star analyst tells investors that the current discounted share price represents a unique buying opportunity. As a result, he initiated coverage with a Buy and set a $96 price target, suggesting 16% upside potential. (To watch O’Hara’s track record, click here)In general, the rest of the Street is on the same page. 4 Buy ratings compared to 1 Hold assigned in the last three months give it a ‘Strong Buy’ analyst consensus. At the $97.20 average price target, shares could surge 18% over the next twelve months. (See LPL Financial stock analysis on TipRanks)IGM Biosciences (IGMS)Also fighting the good fight against cancer, IGM Biosciences is developing its treatments utilizing engineered IgM antibodies. As the company’s IgM-based therapeutics represent a unique approach with the potential to improve efficacy and safety, it’s no wonder Wall Street has this biotech under its microscope.“IGM Biosciences has addressed many of these challenges, making advancements in IgM protein engineering, as well as antibody capture and purification. A key engineering advancement is the ability to convert IgM antibodies into T cell engagers and vehicles for targeted tumor delivery of cytokines and immunostimulatory agents,” explained Jefferies’ Biren Amin.IGMS is especially noteworthy thanks to its lead product candidate, IGM-2323. The drug is a biospecific IgM T-cell engager, with preclinical data implying that it has a greater potency in killing Rituximab resistant cell lines as well as shows overall lower levels of cytokine release in cell lines and non-human primates. This means that the drug could produce greater clinical responses with an improved CRS profile compared to current IgG based biospecifics and CAR-T therapies.Adding to the good news, IGMS is trying to target Dr5 to treat solid tumors and hematological malignancies. If the company can achieve this using its IgM antibody, the implications could be monumental as other attempts to target Dr5 have been unsuccessful.Based on all of the above factors, Amin initiated coverage with a Buy. Along with this bullish call, the 5-star analyst gave IGMS a $25 price target. (To watch Amin’s track record, click here)With only Buy recommendations issued over the last three months, the message is clear: IGMS is a ‘Strong Buy.’ The biotech also boasts 22% upside potential from the current share price. (See IGM Biosciences stock analysis on TipRanks)

  • What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?
    Zacks

    What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

    Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

  • Business Wire

    Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    - Median Progression Free Survival of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 1

  • Benzinga

    The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...

  • Did Hedge Funds Drop The Ball On Deciphera Pharmaceuticals, Inc. (DCPH) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Deciphera Pharmaceuticals, Inc. (DCPH) ?

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the nearly unlimited research abilities of […]

  • Business Wire

    Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    In addition, the Company also presented data from preclinical studies of DCC-3116, a potential first-in-class autophagy inhibitor to treat mutant RAS cancers. “We look forward to continuing Part 2 of our Phase 1b/2 study of rebastinib in combination with paclitaxel with the insights garnered from Part 1 of the study. The Phase 1b/2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor activity and pharmacokinetics of multiple doses of rebastinib in patients with advanced or metastatic solid tumors.

  • Business Wire

    Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Monday, November 4, 2019, to discuss the Company’s financial results and provide a general corporate update. The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 1181263.

  • Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?
    Zacks

    Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?

    Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.

  • Business Wire

    Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Deciphera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that data from four of the Company’s pipeline programs will be presented in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 26-30, 2019 in Boston, MA.

  • American City Business Journals

    Robotics company Boston Dynamics selects new Waltham HQ

    Robotics company Boston Dynamics is moving its headquarters to a redeveloped former U.S. Postal Service distribution center.

  • Deciphera Pharmaceuticals, Inc. (DCPH) Moves to Buy: Rationale Behind the Upgrade
    Zacks

    Deciphera Pharmaceuticals, Inc. (DCPH) Moves to Buy: Rationale Behind the Upgrade

    Deciphera Pharmaceuticals, Inc. (DCPH) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Should Deciphera Pharmaceuticals (NASDAQ:DCPH) Be Disappointed With Their 14% Profit?
    Simply Wall St.

    Should Deciphera Pharmaceuticals (NASDAQ:DCPH) Be Disappointed With Their 14% Profit?

    The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

  • Business Wire

    Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer

    Dr. Sherman brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. Dr. Sherman will be responsible for leading the clinical development and medical affairs strategy for the Company’s pipeline of small molecule drug candidates designed using its proprietary kinase switch control inhibitor platform.

  • Business Wire

    Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

    “For GIST patients who have failed currently approved agents, there exists an urgent need for effective and well-tolerated treatment options,” said Margaret von Mehren, MD, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. “Results from the INVICTUS study support our belief that ripretinib has the potential to transform the current treatment landscape for advanced GIST,” said Steve Hoerter, President and Chief Executive Officer of Deciphera.